Holder Ashley M, Ziemys Arturas
Department of Surgery, Houston Methodist Hospital, Houston, TX, United States.
Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, United States.
Front Oncol. 2020 Sep 11;10:1607. doi: 10.3389/fonc.2020.01607. eCollection 2020.
In staging patients with clinical stage I-II melanoma, the sentinel lymph node (SLN) is the most important prognostic indicator; however, the false negative rate of SLN biopsy (SLNB) is 15%.
Nine patients with clinical Stage I-II melanoma underwent SLNB with repeated intraoperative radiotracer measurements to determine lymphatic transport efficiency (LTE), which was correlated with clinicopathologic data.
LTE demonstrated the potential to predict SLN status. LTE in patients with occult nodal metastasis is 40 times faster than those with negative SLNBs. There was no confounding of LTE by clinicopathologic factors.
LTE may be a novel biomarker for metastasis, with transformative potential for personalized precision diagnostics of early-stage disease and improved patient survival.
在对临床分期为I-II期的黑色素瘤患者进行分期时，前哨淋巴结（SLN）是最重要的预后指标；然而，前哨淋巴结活检（SLNB）的假阴性率为15%。
9例临床I-II期黑色素瘤患者接受了SLNB，并在术中重复进行放射性示踪剂测量以确定淋巴转运效率（LTE），并将其与临床病理数据相关联。
LTE显示出预测SLN状态的潜力。隐匿性淋巴结转移患者的LTE比SLNB阴性患者快40倍。LTE不受临床病理因素的干扰。
LTE可能是一种新的转移生物标志物，对早期疾病的个性化精准诊断和改善患者生存具有变革潜力。
